GoAI
Get started
Climb Bio, Inc. logo

Climb Bio, Inc.

CLYM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$17.28

+$0.26 · +1.53%

Aug 21, 4:00 PM ET

CLYM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

35

Expensive

Momentum

79

Gaining

Sentiment

65

Bullish

Risk resilience

64

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Aoife Brennan BCh MMSc
Listed since
Aug 10, 2021
Employees
28

Market position

Day range

Current $17.28

52-week range

Current $17.28

Open
$17.26
Previous close
$17.02
Volume
957.41K
0.81× average
Average volume
1.19M
Average daily volume
Market cap
989.5M USD
Beta
0.08
Market reference 1
50-day average
$13.308
+29.85% above average
200-day average
$8.0351
+115.06% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
236.1M USD
P/E (TTM)
-20.82×
P/B (TTM)
5.49×
P/S (TTM)
0×
EV / EBITDA
-3.95×
Earnings yield
-22.07%
Free cash flow yield
-20.11%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-37.30%
Return on assets
-35.68%
Return on invested capital
-42.16%

Financial health

Debt / equity
0.01×
Current ratio
15.16×

Financial statements

Income trends

Operating income

−67.88M USD+17.24%

Net income

−59.85M USD+19.01%
Income trends across reported periods−30.43M USD−49.19M USD−67.95M USD−86.71M USDOperating income, FY2021: −35.67M USDOperating income, FY2022: −45.14M USDOperating income, FY2023: −40.28M USDOperating income, FY2024: −82.02M USDOperating income, FY2025: −67.88M USDNet income, FY2021: −47.48M USDNet income, FY2022: −45.24M USDNet income, FY2023: −35.12M USDNet income, FY2024: −73.9M USDNet income, FY2025: −59.85M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −35.67M USD. Operating income FY2022 −45.14M USD. Operating income FY2023 −40.28M USD. Operating income FY2024 −82.02M USD. Operating income FY2025 −67.88M USD. Net income FY2021 −47.48M USD. Net income FY2022 −45.24M USD. Net income FY2023 −35.12M USD. Net income FY2024 −73.9M USD. Net income FY2025 −59.85M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold97K USD————
Gross profit−97K USD————
Research and development46.62M USD14.34M USD15.41M USD26.21M USD23.32M USD
Selling, general, and administrative21.17M USD16.03M USD24.86M USD18.92M USD12.35M USD
Operating expenses67.79M USD82.02M USD40.28M USD45.14M USD35.67M USD
Interest income8.32M USD8.13M USD4.62M USD1.38M USD—
Depreciation and amortization97K USD————
Operating income−67.88M USD−82.02M USD−40.28M USD−45.14M USD−35.67M USD
Net income−59.85M USD−73.9M USD−35.12M USD−45.24M USD−47.48M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
50%
4 beats, 3 misses, 1 met estimate
Average EPS surprise
-9.18%
8 comparable reports
Latest EPS result
-0.18
Estimate -0.21 · Beat by 14.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.11-0.19-0.27-0.35Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual -0.13, estimate -0.15, surprise +13.33%, Beat. Q2 2025, reported May 14, 2025: actual -0.31, estimate -0.15, surprise -106.67%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.13, estimate -0.19, surprise +31.58%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.19, estimate -0.16, surprise -18.75%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.26, estimate -0.2, surprise -30.00%, Miss. Q2 2026, reported May 7, 2026: actual -0.2, estimate -0.26, surprise +23.08%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.18, estimate -0.209, surprise +14.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.21, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$22.60

30.79% upside
Past 12 months12-month forecastHigh $35.00Average $22.60Low $17.00

Recent analyst actions

6 institutions
Truist SecuritiesmaintainBuy
OppenheimermaintainOutperform
BairdmaintainOutperform

CLYM news

defenseworld.net

Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade

Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio…

Read source
defenseworld.net

Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade

Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an…

Read source
seekingalpha.com

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Read source
benzinga.com

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune…

Read source
globenewswire.com

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high…

Read source
globenewswire.com

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer

Read source

CLYM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CLYM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
16.26M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
15.33M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Invesco Dorsey Wright SmallCap Momentum ETF logoInvesco Dorsey Wright SmallCap Momentum ETFDWAS
Market value
6.51M
Weight
1.49%
AUM
434.69M USD
Expense ratio
0.60%
Price / 1D
$114.27+1.10%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.48M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.32M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.47M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.35M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
2.06M
Weight
0.14%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research CLYM

research.disclaimer